Physical Activity and Clinical and Functional Status in COPD

Centre for Research in Environmental Epidemiology, 08003 Barcelona, Catalonia, Spain.
Chest (Impact Factor: 7.13). 04/2009; 136(1):62-70. DOI: 10.1378/chest.08-2532
Source: PubMed

ABSTRACT The mechanisms underlying the benefits of regular physical activity in the evolution of COPD have not been established. Our objective was to assess the relationship between regular physical activity and the clinical and functional characteristics of COPD.
Three hundred forty-one patients were hospitalized for the first time because of a COPD exacerbation in nine teaching hospitals in Spain. COPD diagnosis was confirmed by spirometry under stable conditions. Physical activity before the first COPD hospitalization was measured using the Yale questionnaire. The following outcome variables were studied under stable conditions: dyspnea, nutritional status, complete lung function tests, respiratory and peripheral muscle strength, bronchial colonization, and systemic inflammation.
The mean age was 68 years (SD, 9 years), 93% were men, 43% were current smokers, and the mean postbronchodilator FEV(1) was 52% predicted (SD, 16% predicted). Multivariate linear regression models were built separately for each outcome variable and adjusted for potential confounders (including remaining outcomes if appropriate). When patients with the lowest quartile of physical activity were compared to patients in the other quartiles, physical activity was associated with significantly higher diffusing capacity of the lung for carbon monoxide (Dlco) [change in the second, third, and fourth quartiles of physical activity, compared with first quartile (+ 6%, + 6%, and + 9% predicted, respectively; p = 0.012 [for trend])], expiratory muscle strength (maximal expiratory pressure [Pemax]) [+ 7%, + 5%, and + 9% predicted, respectively; p = 0.081], 6-min walking distance (6MWD) [+ 40, + 41, and + 45 m, respectively; p = 0.006 (for trend)], and maximal oxygen uptake (Vo(2)peak) [+ 55, + 185, and + 81 mL/min, respectively; p = 0.110 (for trend)]. Similarly, physical activity reduced the risk of having high levels of circulating tumor necrosis factor alpha (odds ratio, 0.78, 0.61, and 0.36, respectively; p = 0.011) and C-reactive protein (0.70, 0.51, and 0.52, respectively; p = 0.036) in multivariate logistic regression.
More physically active COPD patients show better functional status in terms of Dlco, Pemax, 6MWD, Vo(2)peak, and systemic inflammation.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The importance of regular physical activity for patients with chronic obstructive pulmonary disease (COPD) is well-established. However, many patients do not meet the recommended daily amount. Accelerometers might provide patients with the information needed to increase physical activity in daily life.
    01/2014; 3(4):e14. DOI:10.2196/ijmr.3056
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and objective: The prevalence of physical comorbidities such as obesity, musculoskeletal or neurological conditions in people with COPD is high, yet little is known about the impact of these physical comorbidities on important health behaviours such as physical activity. The primary aim of the study was to compare the physical activity levels of people with COPD with physical comorbidities (COPD + PC) to people with COPD without physical comorbidities (COPD) and to a healthy age-matched population (control group). Methods: Twenty-five people with COPD + PC (mean (SD) age 73 (11) years, GOLD stage II-IV), 25 people with COPD (70 (9) years, GOLD stage II-IV) and 25 controls (70 (7) years) wore the SenseWear® Pro3 Armband for seven days. Results: Engagement in light intensity physical activity (1.5-3.0 METs) (140 (76) minutes per day (mins/day)) and moderate intensity physical activity (3.0-6.0 METs) (25 (35) mins/day) in the COPD + PC group was significantly reduced compared to the COPD (231 (76) and 104 (106), respectively) and control group (259 (75) and 114 (57), respectively). In the 16 daytime hours between 6am and 10pm, people with COPD + PC spent a mean (SD) of 771 (98) mins/day engaged in sedentary behaviour (<1.5 metabolic equivalents (METs)). This was significantly greater than the group with COPD (603 (148) mins/day) and the control group (567 (76) mins/day) (p < 0.001). Conclusions: People with COPD + PC had significantly lower daily physical activity levels compared to people with COPD without physical comorbidities and healthy people.
    Respirology 06/2014; DOI:10.1111/resp.12325 · 3.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The study aimed to determine the short and long-term effects of exercise training on exercise capacity and health-related quality of life (HRQoL) compared to usual care in people with dust-related pleural and interstitial respiratory diseases. No previous studies have specifically evaluated exercise training in this patient population. Participants with a diagnosis of a dust-related respiratory disease including asbestosis and asbestos related pleural disease were recruited and randomised to an eight-week exercise training group (EG) or a control group (CG) of usual care. Six-minute walk distance (6MWD), St George's Respiratory Questionnaire (SGRQ) and Chronic Respiratory Disease Questionnaire (CRQ) were measured at baseline, eight weeks and 26 weeks by an assessor blinded to group allocation. Thirty-three of 35 male participants completed the study. Sixty-nine percent of participants had asbestos related pleural disease. At eight weeks, compared to the CG, the EG showed a significantly increased 6MWD (mean difference (95%CI)) 53 metres (32 to 74), improved SGRQ total score, -7 points (-13 to -1) and increased CRQ total score, 6.4 points (2.1 to 10.7). At 26 weeks significant between-group differences were maintained in 6MWD, 45 metres (17 to 73) and CRQ total score, 13.1 points (5.2 to 20.9). Exercise training improved short and long-term exercise capacity and HRQoL in people with dust-related pleural and interstitial respiratory diseases. ANZCTR12608000147381. Date trial registered: 27.03.2008.
    BMC Pulmonary Medicine 01/2014; 14(1):180. DOI:10.1186/1471-2466-14-180 · 2.49 Impact Factor


Available from
Jul 28, 2014